Photoactivated iridium(III) complexes drive pyroptosis–necroptosis synergy for multi‐network photoimmunotherapy of renal cell carcinoma
Smart Molecules · 28.07.2026
DOI: 10.1002/smo2.70087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Smart Molecules, online erschienen am 28.07.2026. Verfasst von Xin Qin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology Qilu Hospital of Shandong University Cheeloo College of Medicine Shandong University Jinan China. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Recurrence and metastasis are the leading causes of mortality in renal cell carcinoma (RCC), and its intrinsic drug resistance further limits effective therapeutic options. Synergistic activation of multiple regulated cell death pathways has recently emerged as a novel approach to overcome therapeutic resistance. Here, we developed two mitochondria‐targeted iridium(III) photosensitizers, Ir‐MT1 and Ir‐MT2, for synergistic photoimmunotherapy of RCC. Upon white‐light irradiation, Ir‐MT1/2 induced severe mitochondrial damage and dysfunction, leading to massive release of mitochondrial contents. Mitochondrial DNA leakage activated the cGAS–stimulator of interferon genes pathway and caspase‐1‐mediated pyroptosis cascade, whereas excessive Ca 2+ efflux promoted RIPK1/RIPK3 phosphorylation and induced necroptosis. These death signals facilitated pore formation by gasdermin D and mixed lineage kinase domain‐like protein in the plasma membrane, resulting in membrane rupture, release of damage‐associated molecular patterns, and immunogenic cell death synergistically. In vivo, Ir‐MT1/2 not only effectively suppressed primary tumor growth but also eliminated distant tumors through activation of anti‐tumor immunity, exhibiting potent therapeutic efficacy and favorable biosafety. Overall, our work provides the evidence that a single iridium complex can simultaneously trigger pyroptosis–necroptosis synergy, overcoming intrinsic drug resistance and offering a promising strategy for multi‐network systemic therapy of RCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology Qilu Hospital of Shandong University Cheeloo College of Medicine Shandong University Jinan China.
- State Key Laboratory of Crystal Materials Shandong University Jinan China.
- Department of Radiation Oncology Qilu Hospital of Shandong University Cheeloo College of Medicine Shandong University Jinan China.
- Department of Medical Oncology Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan China.
- School of Biomedical Engineering Shandong University Jinan China.
- Department of Urology Qilu Hospital of Shandong University Dezhou Hospital Dezhou China.
ORCID-Profile: Ling Pan, Kang-Nan Wang
Zitieren
APA
Qin, X., Chen, M. D., Gao, W., Wang, Y., Liu, L. Q., Teng, Z., Qi, T., Wang, Q., Wang, Y., Li, D., Yan, K., Pan, L., Zhao, Z., Zhao, S., Wang, K. N., Fu, S., & Yu, N. (2026). Photoactivated iridium(III) complexes drive pyroptosis–necroptosis synergy for multi‐network photoimmunotherapy of renal cell carcinoma. Smart Molecules. https://doi.org/10.1002/smo2.70087
Vancouver
Qin X, Chen MD, Gao W, Wang Y, Liu LQ, Teng Z, et al. Photoactivated iridium(III) complexes drive pyroptosis–necroptosis synergy for multi‐network photoimmunotherapy of renal cell carcinoma. Smart Molecules. 2026. doi:10.1002/smo2.70087
BibTeX
@article{Qin2026,
author = {Qin, Xin and Chen, Meng-Di and Gao, Wenqi and Wang, Yiping and Liu, Lin-Qing and Teng, Zhen and Qi, Tienan and Wang, Qiyuan and Wang, Yuxuan and Li, Daoxiang and Yan, Keqiang and Pan, Ling and Zhao, Zhongwei and Zhao, Shuo and Wang, Kang-Nan and Fu, Shuai and Yu, Nengwang},
title = {Photoactivated iridium(III) complexes drive pyroptosis–necroptosis synergy for multi‐network photoimmunotherapy of renal cell carcinoma},
journal = {Smart Molecules},
year = {2026},
doi = {10.1002/smo2.70087}
}
EUVIMED